Diabetes Mellitus: Early Stage Outlook [2018]

Maximum Purchase:
1 unit
Publication Date:
September 2018
Adding to cart… The item has been added

Are novel technologies set to revolutionise diabetes? 

Diabetes is a chronic disease that requires lifelong management; however, rapid developments in innovative diabetes technologies (D-tech) have greatly improved the outcomes for patients. On the horizon are next generation products; from insulin pumps with CGM-connectivity to ‘smart’ insulin technology and bioengineered therapies with a view to producing bio-artificial pancreas.What will be hot in D-tech and which products and vendors standout? Want to find out more?

Learn how KOLs see the D-tech market evolving in Diabetes Mellitus: Early Stage Outlook (2018). Eight of the world’s leading US and European KOLs provide candid insights on key emerging technologies for the management of diabetes.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • How do experts view the advances and the evolution of diabetes technology? What impact is D-tech having and how will the treatment landscape evolve over the next decade?
  • Abbott, Medtronic, Dexcom, Senseonics and others have markedly changed the CGM landscape, but which companies are best positioned to develop and commercialise next-generation D-tech? What do KOLs think?
  • How do experts view the developments in the non-invasive insulin systems? Is there a need for oral insulins and can the challenges of bioavailability and dose variability be overcome?
  • Smartphone apps such are increasingly being used to collect patient data but how will app technology evolve over the coming years? What advice do experts have for developers of diabetes apps?
  • Smart insulin pen technology is widely available but smart pills have yet to appear in diabetes. Can digital pills improve compliance and will patients be happy to be tracked?
  • How do experts view telemedicine and digital clinics? Technology is disrupting the way healthcare is provided with companies such as Babylon Health and HealthTap offering virtual care services, but can chatbots replace physicians?
  • How do KOLs view the current hybrid closed-loop systems? Next generation products like Medtronic’s 690G system aims to make automated bolus insulin delivery a reality but will they be effective?
  • Which artificial pancreas (AP) system will be the first to market? Beta Bionics, Bigfoot Biomedical, Cellnovo Diabeloop, Insulet, Medtronic and others are competing but which programmes stand out?
  • How do experts view the potential of glucose-responsive insulins (GRIs)? Several smart insulin R&D programmes are currently underway but what challenges lie ahead and can they be overcome?
  • How do experts see the gene therapy and bio-artificial pancreas technology? Companies such as ViaCyte (PEC-Encap) and Renova Therapeutics (RT-200) are developing products but are they feasible?
  • How do KOLs view the long-term outlook for D-tech? How will the treatment of diabetes evolve over the next decade?
Request sample pages

Back to the top


I can think of several people that I've seen who after starting continuous glucose monitoring with a flash glucose monitor have been able to reduce their A1C by two percent, have managed to significantly reduce the number of hypoglycaemic episodes that they've had and also actually just feel so much more confident in managing their diabetes.”
EU Key Opinion Leader

“They [manufacturers/developers of D-tech] need to think, who is the target population? And they need to do their calculations for investors based on the realistic assessment of who actually is the target population. They need to be able to prove to clinicians like me that they've thought about what are the metrics of success. And thirdly, they need to take a cold, hard look and ask themselves the question, why should someone pay for this?”
US Key Opinion Leader

Key areas of research

  • Innovation in glucose sensor technology (e.g. invasive and non-invasive CGM systems)
  • Non-invasive insulin delivery systems (e.g. oral/transdermal/pulmonary/nasal delivery)
  • Smart devices (e.g. skin patches, lenses, smart socks, apps)
  • Smart pill technology
  • Digital clinics/telemedicine
  • Big data, analytics and tools for data management
  • Closed-loop systems (e.g. artificial pancreas)
  • Glucose-responsive insulin technology
  • Gene therapy, bio-artificial pancreas systems and bioengineered products (e.g. PEC-Encap, encapsulated cell therapies, RT-200)
  • Long-term outlook: impact on diabetes care

KOLs interviewed

KOLs from North America and Europe

  • Anonymous German KOL, MD, PhD; Endocrinologist and Professor in Diabetes, Leading clinical research organisation, Germany
  • Dr Hood Thabit, MD, PhD; Consultant Diabetologist & Honorary Senior Lecturer, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust / University of Manchester, Manchester, UK
  • Prof. David Kerr, MBChB, MD, FRCPE; Director of Research and Innovation, William Sansum Diabetes Center, Santa Barbara, CA, USA
  • Prof. Jay S Skyler, MD, MACP; Professor and Deputy Director, Diabetes Research Institute, University of Miami Miller School of Medicine, Florida, USA
  • Prof. Osama Hamdy, MD, PhD, FACE; Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Program, Joslin Diabetes Center, Associate Professor of Medicine, Harvard Medical School, MA, USA
  • Prof. Pierre Yves Benhamou,  MD, PhD; Head, Clinique d'Endocrinologie Diabétologie Nutrition, Professor of Endocrinology and Metabolism, CHU de Grenoble, Université Joseph Fourier, France
  • Prof. Vivian Fonseca, MD, FRCP; Professor of Medicine and Pharmacology, Assistant Dean for Clinical Research, Chief, Section of Endocrinology, Tulane University Health Sciences Centre, New Orleans, LA, USA
  • Prof. Richard Holt, MA, MB BChir, PhD, FRCP, FHEA; Professor in Diabetes and Endocrinology, Faculty of Medicine, University of Southampton, UK

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.